Most patients with celiac disease are positive for either HLA-DQA1*05:01-DQB1*02 (DQ2.5) or DQA1*03:01-DQB1*03:02 (DQ8). Remaining few patients are usually DQA1*02:01-DQB1*02 (DQ2.2) carriers. Screenings of populations with high frequencies of these HLA-DQA1-DQB1 haplotypes report a 1% to 3% celiac disease prevalence. The aim was to determine the prevalence of HLA-DQ risk haplotypes for celiac disease in Ethiopian children. Dried blood spots collected from 1193 children from the Oromia regional state of Ethiopia were genotyped for HLA-DQA1 and DQB1 genotyping using an asymmetric polymerase chain reaction (PCR) and a subsequent hybridization of allele-specific probes. As references, 2000 previously HLA-genotyped children randomly selected from the general population in Sweden were included. DQ2.2 was the most common haplotype and found in 15.3% of Ethiopian children, which was higher compared with 6.7% of Swedish references (P < .0001). Opposed to this finding, DQ2.5 and DQ8 occurred in 9.7% and 6.8% of Ethiopian children, which were less frequent compared with 12.8% and 13.1% of Swedish references, respectively (P < .0001). The DQ2.5-trans genotype encoded by DQA1*05-DQB1*03:01 in combination with DQ2.2 occurred in 3.6% of Ethiopian children, which was higher compared with 1.3% of Swedish references (P < .0001). However, when children with moderate high to very high-risk HLA genotypes were grouped together, there was no difference between Ethiopian children and Swedish references (27.4% vs 29.0%) (P = .3504). The frequency of HLA risk haplotypes for celiac disease is very similar in Ethiopian and Swedish children. This finding of importance will be useful in future screening of children for celiac disease in Ethiopia.
1 | INTRODUCTION

Knowing the distribution of HLA genotypes has proven to be useful for the prediction of celiac disease in the general population. Celiac disease is an immune disorder strongly associated with the HLA-DQA1*05:01-DQB1*02:01 (DQ2.5) haplotype and to a lesser extent DQA1*03:01-DQB1*03:02 (DQ8) haplotype. Individuals carrying at least one copy of the risk molecule DQ2.5 and/or DQ8 could account for more than 90% celiac disease. Most cases of celiac disease without either of these two haplotypes are positive for the DQA1*02:01-DQB1*02:02 (DQ2.2) haplotype. Subjects positive for the DQ2.2 and DQA1*05-DQB1*03:01 haplotypes can also form DQ2.5 molecule in trans position, encoded by the DQA1*05 and DQB1*02 alleles in different parental chromosomes. Individuals being homozygote for DQ2.5 and those carrying the DQ2.5/DQ2.2 genotype are at a higher risk than those with only one DQ2.5 haplotype. Similarly, homozygosity for DQ2.2 increases the risk over one haplotype. In addition to the genetic factors also various environmental factors are supposed to contribute to the disease risk.

Celiac disease is particularly common in the Nordic countries affecting 2% to 3% of the general population and often co-occurs in the same individual with type 1 diabetes. A plausible explanation for the high prevalence there is the high proportion of HLA-DQ2.5 and DQ8 carriers with susceptibility for the celiac disease and found in approximately 40% of the general population. Autoimmune diseases, like celiac disease, are expected to be rare in many developing countries. The variation in the distribution of HLA-DQ2.5 and DQ8 among the general population may explain the difference in the prevalence between different geographical regions. In Western Europe, the Middle East and North Africa, where the prevalence of the celiac disease is high, the distribution of HLA-DQ2.5 is reaching 20% and that of DQ8 in 10% in some regions compared with 10% respective 5% in Southeast Asia and China, where celiac disease is less frequent. In contrast to most African countries, some parts of North Africa have a high prevalence of celiac disease (5.6%), which is partly explained by a very high frequency of DQ2.5 carriers. On the other hand, the prevalence of HLA-DQ2.5 and DQ8 as well as celiac disease is still mainly unknown in sub-Saharan African countries including Ethiopia.

Ethiopia is one of the developing sub-Saharan countries with a population of approximately 100 million inhabitants with diversified ethnicities, which makes it the second-most populated country in Africa after Nigeria. To our knowledge, only one previous small study has estimated the frequency of HLA genotypes in the Ethiopian general population and showed a proportion of HLA susceptible individuals in Ethiopia comparable with Northern Europe. The aim of the present study was to extend those previous investigations to determine the distribution of HLA-DQ haplotypes and genotypes in an Ethiopian birth cohort and compare the prevalence with a HLAsymptom Swedish birth cohort prospectively followed for type 1 diabetes and celiac disease.

2 | MATERIALS AND METHODS

2.1 | Study population

The Traditional Ethiopian Food (TEF) study is an observational prospective screening study that follows a birth cohort for a celiac disease selected from the general population at three health centers in Adama located in the Oromia regional state, which is the largest of the nine regional states in Ethiopia. The overall goal of the TEF study is to determine the prevalence of celiac disease, and moreover, to identify what are the genetic and environmental factors that trigger or protect Ethiopian children from celiac disease. After informed consent by the guardian, a drop of blood from a finger stick was collected from the child on a filter paper at 9 months of age. Children enrolled in the study are followed annually with yearly visits and collection of blood samples between 24 months and 4 years of age. Between 1 April 2018 and 30 October 2019, parents of 1389 children were asked to participate of whom 1253 (90.0%) accepted participation and 1193 of 1253 (95.2%) were successfully HLA genotyped. Included for comparisons were 2000 previously HLA-genotyped Swedish children randomly selected from 35 690 newborns in the Diabetes Prediction in Skåne (DiPiS) study, a longitudinal study with the main aim to predict type 1 diabetes and celiac disease in the general population.

2.2 | HLA genotyping

HLA typing was performed at the Immunogenetics Laboratory at the University of Turku, Finland as described in the previous studies. After a “full-house” HLA-DQB1 typing presence of DQA1*02:01, DQA1*03 and DQA1*05 were genotyped when informative for deducing common haplotypes. In the same manner, the genotypes HLA-DQA1 and HLA-DQB1 genotypes were determined for the DiPiS study by PCR and sequence-specific probes as described in the previous study. In the DiPiS study series, only a part of DQB1*03:01 positive samples were genotyped for
DQA1*03 and DQA1*05 (N = 77) and also only a part of DQB1*03:03 positive samples for DQBA1*02:01 and DQA1*03 (N = 67). Distribution of haplotypes in these samples were used for estimation their proportion in the whole cohort. HLA risk classifications for celiac disease are summarized in Table 1 and were stratified according to having very low risk to very high risk as described previously.8,21,25-27

### Table 1 Classification of HLA risk genotypes for celiac disease associated according to different DQ molecule combinations

| Celiac disease risk | HLA-DQ genotype status |
|---------------------|------------------------|
| Very high risk      | DQ2.5/DQ2.5            |
|                     | DQ2.5/DQ2.2            |
| Moderate risk       | DQ2.5/DQ8              |
|                     | DQ2.5_trans            |
|                     | DQ2.5/X                |
|                     | DQ2.2/DQ2.2            |
|                     | DQ8/DQ8                |
|                     | DQ8/DQ2.2              |
| Low risk            | DQ2.2/X                |
|                     | DQ8/X                  |
| Very low risk       | DQX/X                  |

Note: Alleles encoding various molecules: DQA1*02-DQB1*02, DQ2.2; DQA1*05-DQB1*02, DQ2.5; DQA1*03-DQB1*03:02, DQ8; other DQA1-DQB1 combinations, X.

3 | RESULTS

#### 3.1 HLA DQA1-DQB1 haplotypes in Ethiopian children vs Swedish references

The DQ2.2 haplotype was the most common among Ethiopian children and found in 15.3% (364/2386) of haplotypes compared with 6.7% (269/4000) of Swedish references (P < .0001; Table 2). The two haplotypes associated most strongly with CD susceptibility, DQ2.5 (DQA1*05-DQB1*02) and DQ8 (DQA1*03-DQB1*03:02), were found in 9.7% (232/2386) and 6.8% (161/2386) of Ethiopian haplotypes compared with 12.8% (513/4000) and 13.1% (523/4000) of Swedish references, respectively (P < .001). The DQ7.5 (DQA1*05-DQB1*03:01) haplotype was found in 12.0% (285/2386) of Ethiopian haplotypes compared with 9.1% (366/4000) of Swedish references, respectively (P < .001). The DQ2.3 (DQA1*03-DQB1*02) haplotype was common in Ethiopia and found in 4.7% (112/2386) of haplotypes but found in few of the Swedish references (0.1% [4/4000]; P < .0001).

#### 3.2 CD-associated HLA genotypes in Ethiopian children vs Swedish references

Among Ethiopian children, 12.1% (144/1193) were positive for DQ2.5/X and 7.4% (89/1193) for DQ8/X, which were both lower compared with 17.1% (342/2000) and 17.5% (349/2000) of Swedish references, respectively (P < .0001). Similarly, were DQ2.5/DQ8 heterozygotes less common in Ethiopian children compared with Swedish references (Table 3). However, due to the high frequency of the DQ2.2 and DQ7.5 haplotypes was the genotype encoding DQ2.5

trans molecule more common among Ethiopian children as well as DQ2.2/X and DQ2.2/DQ2.2 combinations. There was no difference in frequency of the two HLA genotypes associated with very high risk, DQ2.2/DQ2.5 and DQ2.5/DQ2.5, likewise also DQ2.2/DQ8 and DQ8 homozygotes when Ethiopian children were compared with Swedish references (Table 3).

When children with moderate high to very high-risk HLA genotypes were grouped together (Table 1), there was no difference between Ethiopian children and the Swedish references (27.4% [327/1193] vs 29.0% [579/2000]; P = .3504; Figure 1). The overall frequency of having very low risk was 48.4% (577/1193) in Ethiopian

### Ethical statement

This study was approved by the institutional review board of Armauer Hansen Research Institute (P028/17), National Research Ethics Committee of Ethiopia (Ref. No. 3.10/16/2018), and the ethical committee Lund University (Pro.No.2017/3). A supportive letter was obtained from Oromia national regional state health offices of Ethiopia. Consent was obtained from mothers or legal guardians of each study children. All samples and related questioners were processed and kept by codes without any personnel identity. The DiPiS study was approved by the ethical committee Lund University (LU 490-99).

### Statistical analysis

A descriptive statistic by using SPSS for Windows, version 25; SPSS Inc. Chicago, Illinois was used to calculate the frequencies of the HLA haplotypes, and differences between groups were estimated by the chi-squared test. Bonferroni’s test was used for multiple comparisons. A P-value < .05 was considered statistically significant.
children, which was slightly higher compared with 44.2% (884/2000) of Swedish references ($P = .0222$; Figure 1).

## DISCUSSION

This study estimated the prevalence of HLA-DQ risk haplotypes and genotypes for celiac disease in Ethiopian children and compared the frequencies of a previously HLA-genotyped Swedish birth cohort. The frequency of DQ2.5 haplotype, which is found in most celiac disease patients worldwide\(^6\), was higher in Swedish references than in Ethiopian as well as the DQ8 haplotype, found in most patients without DQ2.5. In contrast, the most frequent haplotype in Ethiopian children was the DQ2.2 haplotype, which was higher compared with Swedish references. Only few patients with CD are DQ2.2 positive without having any of DQ2.5 or DQ8, but in combination

| HLA haplotype                          | Ethiopian cohort | Swedish references | $P$-value |
|----------------------------------------|------------------|--------------------|-----------|
| DQA1*02:01-DQB1*02 (DQ2.2)            | 364              | 269                | <0.0001   |
| (DQA1*01)-DQB1*05:01                  | 341              | 434                | <0.0001   |
| DQA1*05-DQB1*03:01 (DQ7.5)            | 285              | 366                | 0.0004    |
| (DQA1*01)-DQB1*06:02                  | 239              | 560                | <0.0001   |
| (DQA1*01)-DQB1*06:04                  | 238              | 244                | <0.0001   |
| DQA1*05-DQB1*02 (DQ2.5)               | 232              | 513                | 0.0002    |
| DQA1*03-DQB1*03:02 (DQ8)              | 161              | 523                | <0.0001   |
| (DQA1*01)-DQB1*06:03                  | 115              | 234                | 0.0797    |
| DQA1*03-DQB1*02 (DQ2.3)               | 112              | 4                  | <0.0001   |
| (DQA1*01)-DQB1*06:09                  | 95               | 23                 | <0.0001   |
| (DQA1*03/*04)-DQB1*04                 | 80               | 145                | 0.5683    |
| DQA1*02:01-DQB1*03:03                 | 52               | 88                 | 0.9566    |
| DQA1*03-DQB1*03:01                    | 30               | 246                | <0.0001   |
| (DQA1*01)-DQB1*05:03                  | 17               | 81                 | <0.0001   |
| DQA1*03-DQB1*03:03                    | 8                | 67                 | <0.0001   |
| (DQA1*01)-DQB1*05:02/04               | 5                | 65                 | <0.0001   |
| Other haplotypes                       | 12               | 138                | <0.00001  |

| HLA-DQ genotype | Ethiopian cohort | Swedish references | $P$-value |
|-----------------|------------------|--------------------|-----------|
| DQ2.2/X         | 200              | 189                | <0.0001   |
| DQ2.5/X         | 144              | 342                | 0.000025  |
| DQ8/X           | 89               | 349                | <0.0001   |
| DQ2.5_trans     | 43               | 26                 | <0.0001   |
| DQ2.2/DQ2.2     | 39               | 4                  | <0.0001   |
| DQ2.5/DQ2.5     | 26               | 34                 | 0.33681   |
| DQ2.5/DQ2.2     | 22               | 33                 | 0.68474   |
| DQ2.2/DQ8       | 21               | 38                 | 0.77771   |
| DQ8/DQ8         | 18               | 32                 | 0.84147   |
| DQ2.5/DQ8       | 14               | 70                 | <0.0001   |
| X/X             | 577              | 883                | 0.0523    |

Note: Alleles encoding various molecules: DQA1*02:01-DQB1*02, DQ2.2; DQA1*05-DQB1*02, DQ2.5; DQA1*05-DQB1*03:01 together with DQA1*02:01-DQB1*02, DQ2.5_trans; DQA1*03-DQB1*03:02, DQ8; Other DQA1-DQB1 haplotypes including DQA1*05-DQB1*03:01 in other genotype combinations, X.
of DQ7.5 and DQ2.2 the DQ2.5 molecule can still be encoded in trans position. In addition to DQ2.2, Ethiopian children had high frequency of the DQA1*05-DQB1*03:01 haplotype compared with Swedish references. This overall prevalence of children with DQ2.5 in trans position was thus nearly three times as high in Ethiopian compared with Swedish references. When comparing risk molecule frequencies with the Swedish references, the frequencies of the DQ2.2 and DQ2.5 trans molecule were therefore in fact higher among the Ethiopian children, although the opposite was true for DQ2.5 cis and DQ8. In line with our results, another study also found a high frequency of DQ2.2 among the Ethiopian Oromo population (15.5%).

The biggest difference in haplotype distribution between the Ethiopian and Swedish populations was conferred by DQ2.3, which is very rare in Northern Europe but found with relatively high frequency in many Mediterranean countries and in Africa in linkage with several DR alleles and associated with increased risk of type 1 diabetes. Although the DQ2.3 association with type 1 diabetes has been well studied, it is still unknown whether it contributes to an increased risk of CD due to lack of studies. In type 1 diabetes, it is also known to be encoded in trans position in patients carrying the high-risk-associated DQ2/DQ8 genotype. Interestingly, trans encoded DQ2.3 molecules were able to present a deamidated gluten peptide epitopes even more efficiently than the DQ2.5 and DQ8 molecules indicating a possible role in the pathogenesis of the celiac disease.

Differences in frequency of HLA-DQ risk haplotypes among populations may partly explain differences in reported prevalence of celiac disease and/or type 1 diabetes. In the present study, the overall frequency of HLA risk was quite similar between Ethiopian and Swedish children when including all variants of DQ2 (including DQ2.5 in cis or trans position and DQ2.2). The frequencies in our Ethiopian cohort were comparable with results from studies in Algeria (28.3%), Morocco (25%), Libya (34%) and northern India (31.9%). On the other hand, the frequency of DQ2 was higher than the results of studies from Iran (20%), Turkey (18%), Southern India (12.78%), Rwanda (15.5%), Tanzania (13.5%) and Cameroon (7.0%), but lower compared with a study on the Saharawi population (39%), where the prevalence of the celiac disease has been estimated to be the highest in the world.

Our study also showed that the DQ8 haplotype was less frequently found among the Ethiopian children as compared with the Swedish references (6.8% vs 13.1%), but comparable with study findings from Japan (7.6%), Sardinia (5%) and 8.9% of Caucasians in the United States. In addition, we found a higher distribution of DQ8 than in South Africa (2.8%), Saharawi (2.7%), Algeria (2.2%), Italy (2%) and Cameroon (0.6%). Compared with our study, higher frequencies in the review by Alarida were reported from Mexico (28.3%), Turkey (22%), North India (15.6%) and Iran (12%).

Our findings indicate that more than half (51.6%) of the Ethiopian population is carrying any of the DQ2.5, DQ2.2 and DQ8 haplotypes, which was comparable with the Swedish references (55.9%) and other previous studies performed on the general population in Australia (55.9%), Iran (58%), Saudi Arabia (52.7%), but slightly higher than Brazil (43.7%) and Denmark (47.7%). Although this study is the largest HLA-genotyped Ethiopian population to date, it is limited by the fact that children included in the present study were enrolled from only one region and therefore may not represent the whole population in Ethiopia. We can therefore only speculate that our results might partly explain the low reported prevalence of the celiac disease in Ethiopia as compared with Sweden, albeit the true prevalence in the general population is still unknown.

In conclusion, the present study showed that the overall distribution of HLA risk haplotypes for celiac disease is very similar in Ethiopian compared with Swedish children. This new knowledge might be useful in future screening of children from the general population for celiac disease in Ethiopia.

ACKNOWLEDGMENTS

This research was aided by the funds provided by the Swedish Research Council, Swedish Celiac Disease Foundation, Håkanssons Stiftelse and Fållssons Stiftelse. The authors are grateful to all Adama site supporting staffs,
study participants and their families. The authors thank the investigators of Diabetes Prediction in Skåne (DiPiS) from Sweden and the laboratory technicians involved with a DNA sample and subsequent analysis in Immuno- genetics Laboratory, University of Turku, Finland.

CONFLICT OF INTEREST
The authors have declared no conflicting interests.

AUTHOR CONTRIBUTIONS
A.N.G.: substantial contribution to the conception or design of the project, data curation, analysis or interpretation, project administration, drafting and revising the manuscript critically. A.R.: editing and revising the manuscript. T.T.B.: contribution to the conception of the project and revising the manuscript. A.G.: conceptualization and review and editing. J.I.: Substantial contribution to the conception or design of the project, interpretation of data for the work, project administration, resources and supervision, revising the manuscript critically and approve the version to be published. D.A.: substantial contribution to the conception or design of the project, performed HLA typing, analysis, revising the manuscript critically and the conception or design of the project, performed HLA typing, analysis, revising the manuscript critically and approve the version to be published.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Daniel Agardh https://orcid.org/0000-0003-1435-1234

REFERENCES
1. Björck S, Lynch K, Brundin C, et al. Repeated screening can be restricted to at-genetic-risk birth cohorts. J Pediatr Gastroenterol Nutr. 2016;62(2):271-275.
2. Poddighe D, Rebuffi C, De Silvestri A, et al. Carrier frequency of HLA-DQB1*02 allele in patients affected with celiac disease: a systematic review assessing the potential rationale of a targeted allelic genotyping as a first-line screening. World J Gastroenterol. 2020;26(12):1365-1381.
3. Delgado JF, Amengual MJ, Veraguas A, Rodríguez E, de Los Santos MM, Guallarre MP. Paediatric celiac patients carrying the HLA-DR7-DQ2 and HLA-DR3-DQ2 haplotypes display small clinical differences. Acta Paediatr. 2014;103(6):e238-e242.
4. Sollid LM, Thorsby E. HLA susceptibility genes in celiac disease: Genetic mapping and role in pathogenesis. Gastroenterology. 1993;105(3):910-922. http://dx.doi.org/10.1016/0016-5085(93)90912-v.
5. Karell K, Louka AS, Moodie SJ, et al. HLA types in celiac disease patients notCarrying theDQA1*05-DQB1*02(DQ2) heterodimer: results from the EuropeanGenetics cluster on celiac disease. Hum Immunol. 2003;64:469-477.
6. Cabrera CM, Méndez-López IM, Caballero A. Risk variation in celiac disease in a population from Southern Spain: evaluating the influence of the DQB1* 02: 02 allele frequency. Scand J Gastroenterol. 2018;53(3):266-272.
7. Lundin KEA, Scott H, Hansen T, et al. Gliadin-specific, HLA-DQ(α1*0501, β1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med. 1993;178:187-196.
8. Almeida LM, Gandolfi L, Pratesi R, et al. Presence of DQ2.2 associated with DQ2.5 increases the risk for celiac disease. Autoimmune Dis. 2016;2016:5409653.
9. Solid LM, Lie BA. Celiac disease genetics: current concepts and practical applications. Clin Gasterenterol Hepatol. 2005;3:843-851.
10. Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. Nat Rev Genet. 2004;5(12):898-899.
11. Myléus A, Ivarsson A, Webb C, et al. Celiac disease revealed in 3% of Swedish 12-year-olds born during an epidemic. J Pediatr Gastroenterol Nutr. 2009;49(2);170-176.
12. Hanberger L, Birkebaek N, Bjarnason R, et al. Childhood diabetes in the Nordic countries: a comparison of quality registries. J Diabetes Sci Technol. 2014;8(4):738-744.
13. Popp A, Mäki M. Changing pattern of childhood celiac disease epidemiology: contributing factors. Front Pediatr. 2019;7:357.
14. Viken MK, Flam ST, Skrivarhaug T, et al. HLA class II alleles in Norwegian patients with coexisting type 1 diabetes and celiac disease. HLA. 2017;89(5):278-284.
15. Camarca ME, Mozzello E, Nugnes R, et al. Celiac disease in type 1 diabetes mellitus. Ital J Pediatr. 2012;38(1):10.
16. Husby S, Koletzko S, Korponay-Szabo I, et al. European Society for Pediatric Gastroenterology, Hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54(1):136–160.
17. Kang J, Kang A, Green A, et al. Systematic review: worldwide variation in the frequency of coeliac disease and changes over time. Aliment Pharmacol Ther. 2013;38(3):226-245.
18. Rostami-Nejad M, Romanos J, Rostami K, et al. Allele and haplotype frequencies for HLA-DQ in Iranian celiac disease patients. World J Gastroenterol. 2014;20(20):6302-6308.
19. Fort M, de Stefano GF, Cambon-Thomsen A, et al. HLA class II allele and haplotype frequencies in Ethiopian Amhara and Oromo populations. Tissue Antigens. 1998;51:327-336.
20. Larsson HE, Hansson G, Carlsson A, et al. Children developing type 1 diabetes before 6 years of age have increased linear growth independent of HLA genotypes. Diabetologia. 2008;51(9):1623-1630.
21. Björck S, Brundin C, Lörinc E, Lynch KF, Agardh D. Screening detects a high proportion of celiac disease in young HLA-genotyped children. J Pediatr Gastroenterol Nutr. 2010;50:49-53.
22. Mikk ML, Kiviniemi M, Laine AP, et al. The HLA-B*39 allele increases type 1 diabetes risk conferred by HLA-DRB1*04:04-DQB1*03:02 and HLA-DRB1*08-DQB1*04 class II haplotypes. Hum Immunol. 2014;75(1):65-70.
23. Ilonen J, Kiviniemi M, Lempainen J, et al. Genetic susceptibility to type 1 diabetes in childhood - estimation of HLA class II associated disease risk and class II effect in various phases of islet autoimmunity. Pediatr Diabetes. 2016;17 (Suppl 22):8-16.
24. Larsson HE, Lynch K, Lernmark B, et al. Diabetes-associated HLA genotypes affect birthweight in the general population. *Diabetologia*. 2005;48(8):1484-1491.

25. Al-Hussaini A, Alharthi H, Osman A, et al. Genetic susceptibility for celiac disease is highly prevalent in the Saudi population. *Saudi J Gastroenterol*. 2018;24(5):268-273.

26. Joshi KK, Haynes A, Davis EA, D’Orsogna L, McLean-Tooke A. Role of HLA-DQ typing and anti-tissue transglutaminase antibody titers in diagnosing celiac disease without duodenal biopsy in type 1 diabetes: a study of the population-based pediatric type 1 diabetes cohort of Western Australia. *Pediatr Diabetes*. 2019;20(5):567-573.

27. Megiorni F, Mora B, Bonamico M, et al. HLA-DQ and risk gradient for celiac disease. *Hum Immunol*. 2009;70(1):55-59.

28. Noble JA, Johnson J, Lane JA, Valdes AM. Race-specific type 1 diabetes risk of HLA-DR7 haplotypes. *Tissue Antigens*. 2011;78(5):348-351.

29. Noble JA, Johnson J, Lane JA, Valdes AM. HLA class II genotyping of African American type 1 diabetic patients reveals associations unique to African haplotypes. *Diabetes*. 2013;62(9):3292-3299.

30. El-Amir MI, El-Feky MA, Laine AP, et al. Risk genes and autoantibodies in Egyptian children with type 1 diabetes - low frequency of autoantibodies in carriers of the HLA-DRB1*04:05-DQA1*03-DQB1*02 risk haplotype. *Diabetes Metab Res Rev*. 2015;31(3):287-294.

31. Tollefsen S, Hotta K, Chen X, et al. Structural and functional studies of trans-encoded HLA-DQ2.3 (DQA1*03:01/DQB1*02:01) protein molecule. *J Biol Chem*. 2012;287(17):13611-13619.

32. Sanchez-Mazas A, Buhler S, Nunes JM. A new HLA map of Europe: regional genetic variation and its implication for peopling history, disease-association studies and tissue transplantation. *Hum Hered*. 2013;76(3-4):162-177.

33. Peterson TA, Bielawny T, Lacap P, et al. Diversity and frequencies of HLA class I and class II genes of an east African population. *Open J Gen*. 2014;04(02):99-124.

34. Alarida K, Harown J, Di Pierro MR, et al. HLA-DQ2 and -DQ8 genotypes in celiac and healthy Libyan children. *Dig Liver Dis*. 2010;42(6):425-427.

35. Catassi C, Rätsch MDMI-M, Virgiliis SD, et al. The distribution of DQ genes in the Saharawi population provides only a partial explanation for the high celiac disease prevalence. *Tissue Antigens*. 2001;58:402-406.

36. Klitz W, Maiers M, Spellman S, et al. New HLA haplotype frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. *Tissue Antigens*. 2003;62:296-307.

37. Anderson RP, Henry MJ, Taylor R, et al. A novel serogenetic approach determines the community prevalence of celiac disease and informs improved diagnostic pathways. *BMC Med*. 2013;11:188.

38. Selleski N, Almeida LM, FDa A, et al. Prevalence of celiac disease predisposing genotypes, including HLA-DQ2.2 variant, in Brazilian children. *Arq Gastroenterol*. 2018;55(1):82-85.

39. Almeida FC, Gandolfi L, Costa KN, et al. Frequency of HLA-DQ, susceptibility genotypes for celiac disease, in Brazilian newborns. *Mol Genet Genomic Med*. 2018;6(5):779-784.

40. Karhus LL, Thuesen BH, Skaaby T, et al. The distribution of HLA DQ2 and DQ8 haplotypes and their association with health indicators in a general Danish population. *United European Gastroenterol J*. 2018;6(6):866-878.

---

**How to cite this article:** Gudeta AN, Ramelius A, Balcha TT, Girma A, Ilonen J, Agardh D. Distribution of HLA-DQ risk genotypes for celiac disease in Ethiopian children. *HLA*. 2020;96:681-687. [https://doi.org/10.1111/tan.14119](https://doi.org/10.1111/tan.14119)